Trial intelligence / Profile preview

Low-dose dexmedetomidine effect on propofol ED50 for upper gastrointestinal endoscope insertion

ChiCTR2200055952Phase 4Completed

Sponsor
Beijing Friendship Hospital
Start
Jan 2022
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial comparing Propofol alone with Dexmedetomidine + propofol (2 arms). Primary endpoint: Median effective dose (ED50) of propofol for successful upper gastrointestinal endoscope insertion. Started Jan 2022; status: completed.

02

Drugs

propofoldexmedetomidine

Beyond the preview

Go deeper on ChiCTR2200055952.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2200055952.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call